Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
BriaCell Therapeutics Corp. Common Shares
BCTX | US
3.75
USD-0.14
-3.60%
BCTX | US
Loading StockChartView...
About BriaCell Therapeutics Corp. Common Shares
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/04/2024
As of date
27/03/2026
Close
3.75
Open
3.90
High
4.00
Low
3.72
BriaCell Therapeutics Corp. an immuno-oncology-focused biotechnology company engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver Canada.
View LessBCTX | US
Risk
75.7
Sharpe
-0.70
Luna's Score
30/100
Recommendation
Sell
Luna says (BCTX | US)
What's Working
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
66.0%1 month
75.7%3 months
157.5%6 months
139.9%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
17.03
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
-1.38
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-35.25M
MarketCap
134.58M
MarketCap(USD)
134.58M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-206.01
Short ratio
0.04
Short perc.
1.56
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.88
Range1M
0.99
Range3M
8.50
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.27
Price X volume
1.14M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.38 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 17.03 | 15.55 | Par |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 157.49 | 72.80 | Riskier |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 134.58M | 3.66B | Emerging |
